US Tech 100

21,052.80

0.65%

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

ABBV AbbVie Inc

191.37

0.77 (0.40%)

Pre Market

Last Updated: 04:30:38

Delayed by 15 minutes

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]

AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jan 2025 to Feb 2025

AbbVie (NYSE:ABBV)
Historical Stock Chart
From Feb 2024 to Feb 2025

AbbVie Inc News

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
Friday 7 February 2025 (3 days ago) • Edgar (US Regulatory)

U.S. FDA Approves EMBLAVEO™ (aztreonam and avibactam) for the Treatment of Adults With Complicated Intra-Abdominal Infections With Limited or No Treatment Options
Friday 7 February 2025 (3 days ago) • PR Newswire (US)

Allergan Aesthetics Invites Consumers to Join the Faces of Natrelle® Campaign
Thursday 6 February 2025 (4 days ago) • PR Newswire (US)

Form 8-K - Current report
Wednesday 5 February 2025 (5 days ago) • Edgar (US Regulatory)

Allergan Aesthetics, the American Society of Plastic Surgeons (ASPS) and The Aesthetic Society Release Two New Engaging LIMITLESS Videos Celebrating Women Surgeons
Wednesday 5 February 2025 (5 days ago) • PR Newswire (US)

Form 8-K - Current report
Friday 31 January 2025 (1 week ago) • Edgar (US Regulatory)

AbbVie Reports Full-Year and Fourth-Quarter 2024 Financial Results
Friday 31 January 2025 (1 week ago) • PR Newswire (US)

Allergan Aesthetics launches new AA Signature Program at IMCAS 2025 to redefine patient-centric, multimodal treatment plans
Wednesday 29 January 2025 (2 weeks ago) • PR Newswire (US)

Allergan Aesthetics unveils new AA Signature Program and immersive booth at IMCAS World Congress 2025
Friday 24 January 2025 (2 weeks ago) • PR Newswire (US)

AbbVie Completes Acquisition of Nimble Therapeutics
Thursday 23 January 2025 (3 weeks ago) • PR Newswire (US)

AbbVie and Neomorph Announce Collaboration to Develop Molecular Glue Degraders for Oncology and Immunology
Thursday 23 January 2025 (3 weeks ago) • PR Newswire (US)

AbbVie and Simcere Zaiming Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma
Monday 13 January 2025 (4 weeks ago) • PR Newswire (US)

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

ABBV AbbVie Inc

AbbVie Inc News

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

ABBV AbbVie Inc

AbbVie Inc News

Your Recent History

Company

Business

Popular

Get The App

Go Ad-Free